Leukogene Therapeutics Inc.
Biotechnology company developing MHC class II-targeted recombinant protein immunotherapies that conjugate tumor-associated antigens to direct and mobilize the immune system against difficult-to-treat cancers. Headquartered in Charleston, SC, and originating as a spin-out from the Medical University of South Carolina (MUSC), the company advances candidates from discovery and preclinical proof-of-concept toward first-in-human clinical development.
Industries
N/A
Nr. of Employees
small (1-50)
Leukogene Therapeutics Inc.
Blue Sky Labs, QE308C-D, 280 Calhoun St., Charleston, SC 29425
Patents
Products
MHCII-targeted recombinant protein candidate directed at CD33
A recombinant protein therapeutic that conjugates a CD33 tumor-associated antigen to an MHC class II-targeting moiety developed as a clinical candidate for acute myelogenous leukemia and related hematologic malignancies.
MHCII-targeted recombinant protein candidate directed at mesothelin
A recombinant protein therapeutic that conjugates a mesothelin tumor-associated antigen to an MHC class II-targeting moiety developed for pancreatic ductal adenocarcinoma and other solid tumors expressing mesothelin.
MHCII-targeted recombinant protein candidate directed at CD33
A recombinant protein therapeutic that conjugates a CD33 tumor-associated antigen to an MHC class II-targeting moiety developed as a clinical candidate for acute myelogenous leukemia and related hematologic malignancies.
MHCII-targeted recombinant protein candidate directed at mesothelin
A recombinant protein therapeutic that conjugates a mesothelin tumor-associated antigen to an MHC class II-targeting moiety developed for pancreatic ductal adenocarcinoma and other solid tumors expressing mesothelin.
Services
Partnered preclinical research and translation of antigen-targeted immunotherapies with academic and industry collaborators.
Project leadership and CMC support to advance biologic therapeutics from development toward clinical readiness.
Partnered preclinical research and translation of antigen-targeted immunotherapies with academic and industry collaborators.
Project leadership and CMC support to advance biologic therapeutics from development toward clinical readiness.
Expertise Areas
- Cancer immunotherapy
- Recombinant protein therapeutics
- Protein engineering and biochemistry
- Preclinical oncology models and translational research
Key Technologies
- Recombinant protein therapeutics
- MHC class II targeting
- Tumor-associated antigen conjugation
- Protein engineering
News & Updates
Announcement of the appointment of Dr. Sandeep Gupta as CEO and summary of his industry background; restates company focus on MHCII-targeted recombinant immunotherapies and clinical development candidates in AML and pancreatic cancer.
Description of an SCRA award and collaborative project involving MUSC and Leukogene to support translational development of a recombinant protein cancer vaccine and other innovations.
Announcement of the appointment of Dr. Sandeep Gupta as CEO and summary of his industry background; restates company focus on MHCII-targeted recombinant immunotherapies and clinical development candidates in AML and pancreatic cancer.
Description of an SCRA award and collaborative project involving MUSC and Leukogene to support translational development of a recombinant protein cancer vaccine and other innovations.